Zusammenfassung
Die Parkinsonsche Krankheit ist eine fortschreitende neurologische Erkrankung des extrapyramidalmotorischen Systems, von der 1% der Bevölkerung über 65 Jahre betroffen ist. Ursache ist eine in ihrer Ätiologie unbekannte Degeneration von Nervenzellen in der Substantia nigra, die zu einem „striatalen“ Dopaminmangelsyndrom führt und mit einer erhöhten cholinergen Aktivität einhergeht.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Ahlskog JE, Uitti RJ (2010): Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74: 1143-1148.
Anonymus (2008): Rotigotine: Parkinsons disease: a step backward. Prescrire Int 17: 60.
Arnold G, Kupsch A (2000): Hemmung der Catechol-O-Methyltransferase. Optimierung der dopaminergen Therapie beim idiopathischen Parkinsonsyndrom mit Entacapone. Nervenarzt 71: 78-83.
Birkmayer W, Hornykiewicz O (1961): Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien klin Wschr 78: 787-788.
Chen JJ, Swope DM (2005): Clinical pharmacology of rasagiline: a novel, second-gene- ration propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878-894.
Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinsons disease. Cochrane Database Syst Rev. 2003;(1):CD003468.
Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinsons disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554.
Deutsche Gesellschaft für Neurologie (2008): Parkinson-Syndrome. Internet: www.dgn. org/images/stories/dgn/leitlinien/LL2008/ll08kap_009.pdf
European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf
European Medicines Agency (EMA) (2006): Rotigotin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.eu.int/humandocs/PDFs/EPAR/ neupro/ 062606de1.pdf
Fahn S and the Parkinson Study Group (2005): Does levodopa slow or hasten the rate of progression of Parkinsons disease? J Neurol 252 (Suppl 4): IV37-IV42.
Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 inves- tigators (2007): Rotigotine transdermal patch in early Parkinsons disease: a rando- mized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398-2404.
Huntington Study Group (2006): Tetrabenazine as antichorea therapy in Huntington dis- ease: a randomized controlled trial. Neurology 66: 366-372.
Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K (2004): Monoamine oxidase type B inhibitors in early Parkinsons disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329: 593-599.
Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinsons disease. Cochrane Database Syst Rev. 2003;(2):CD003735.
Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and 3g levodopa combined with selegiline in patients with early, mild Parkinsons disease. Parkinsons Disease Research Group of the United Kingdom. BMJ 311: 1602-1607.
Lees AJ, Hardy J, Revesz T (2009): Parkinsons disease. Lancet 373: 2055-2066.
Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Ten-year follow-up of three dif- ferent initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687-1694.
Mejer Nielsen B (1983): Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372-375.
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010): Missing pieces in the Parkinson's dis- ease puzzle. Nat Med 16: 653-661.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (2009): A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268-1278.
Parkinson Study Group (2004): A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561-566.
Parkinson Study Group (2005): A randomized placebo-controlled trial of rasagiline in le- vodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241-248.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491.
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005): Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947-954.
Rascol O, Lozano A, Stern M, Poewe W (2011): Milestones in Parkinson's disease thera- peutics. Mov Disord 26: 1072-1082.
Samanta J, Hauser RA (2007): Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 8: 657-664.
Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149-158.
Scottish Intercollegiate Guidelines Network (2010): Diagnosis and pharmacological management of Parkinson's disease. A national clinical guideline. Internet: www.sign.ac.uk/pdf/sign113.pdf
Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson's disease. Neurology 50 (Suppl 6): S18-S22; discussion S44-S48.
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010): Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68: 18-27.
The Parkinson Study Group (1993): Effects of tocopherol and deprenyl on the progression of disability in early parkinson's disease. N Engl J Med 328: 176-183.
The Parkinson Study Group (2004): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044-1053.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Medizin Verlag Berlin, Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2012). Parkinsonmittel. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_38
Download citation
DOI: https://doi.org/10.1007/978-3-642-29242-2_38
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29241-5
Online ISBN: 978-3-642-29242-2
eBook Packages: Medicine (German Language)